8-K/A: Viatris Exercises Option to Sell Over-the-Counter Business to Cooper Consumer Health

Viatris has finalized an agreement to sell its over-the-counter products business to Cooper Consumer Health after exercising a previously granted option.

Summary

• Viatris Inc. has officially exercised its option to sell its over-the-counter (OTC) products business to Cooper Consumer Health SAS.
• The transaction agreement was finalized on January 29, 2024, following the completion of consultation procedures with employee representatives.
• The sale includes substantially all of Viatris's OTC products business, related assets, and liabilities.
• The deal is subject to customary closing conditions, including regulatory approvals from the European Commission and the French Ministry of Economy.
• Regulatory consents have already been received from the Presidency of the Italian Council of Ministries and the Commission for Protection of Competition of the Republic of Serbia.
• The transaction involves the sale of equity interests in several European subsidiaries of Viatris.
• The agreement includes a purchase price adjustment mechanism based on working capital, cash, and debt at closing.
• The final purchase price will also include a contingent additional amount based on future performance.
• The closing is expected to occur ten business days after all conditions are met, with potential delays to the end of the month under certain circumstances.

Sentiment

Score: 7

Explanation: The document is generally positive, indicating progress in the sale of the OTC business. However, it also acknowledges risks and uncertainties, which tempers the overall sentiment.

Positives

• The exercise of the option and signing of the transaction agreement represent a significant step towards the completion of the sale.
• The deal includes a mechanism for purchase price adjustments, ensuring a fair valuation at closing.
• The inclusion of a contingent additional amount provides potential for additional value based on future performance.
• Regulatory approvals from Italy and Serbia have already been secured, indicating progress in the approval process.

Negatives

• The transaction is still subject to several closing conditions, including regulatory approvals, which could potentially delay or prevent the deal from closing.
• The purchase price is subject to adjustments, which could result in a lower final payment than initially anticipated.
• The deal includes a contingent additional amount, which may not be realized if future performance targets are not met.

Risks

• The transaction may not be completed on the expected timelines or at all.
• Conditions set forth in the agreements may not be satisfied or waived.
• The total transaction value and expected proceeds may not be realized due to purchase price adjustments or failure to achieve contingent consideration conditions.
• Viatris may be unable to realize the intended benefits or achieve the intended goals of the transaction.
• Goodwill or other impairment charges or losses related to the divestiture may occur.

Future Outlook

The document contains forward-looking statements regarding the completion of the transaction, which are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied.

Industry Context

This announcement reflects a trend of pharmaceutical companies divesting non-core assets to focus on strategic priorities. The sale of the OTC business allows Viatris to streamline its operations and potentially improve its financial position.

Comparison to Industry Standards

• The divestiture of non-core assets is a common strategy in the pharmaceutical industry, with companies like Teva and Novartis also undertaking similar actions to optimize their portfolios.
• The use of purchase price adjustments and contingent payments is a standard practice in M&A transactions, particularly in the pharmaceutical sector, to account for uncertainties and future performance.
• The regulatory approval process for such transactions is typically complex and time-consuming, involving multiple jurisdictions, as seen in other similar deals.
• The timeline for closing, which is contingent on regulatory approvals, is consistent with industry norms for transactions of this size and complexity.

Stakeholder Impact

• Shareholders: The sale of the OTC business may impact the company's stock price and future financial performance.
• Employees: The transaction may result in changes to employment for those involved in the OTC business.
• Customers: The sale may lead to changes in the availability or branding of OTC products.
• Suppliers: The transaction may affect existing supply agreements related to the OTC business.
• Creditors: The sale may impact the company's debt structure and credit rating.

Next Steps

• Obtain regulatory approvals from the European Commission and the French Ministry of Economy.
• Satisfy all other closing conditions outlined in the transaction agreement.
• Finalize the purchase price adjustments based on working capital, cash, and debt at closing.
• Complete the transfer of assets and liabilities to Cooper Consumer Health.
• Potentially receive a contingent additional amount based on future performance.

Key Dates

Keywords

Viatris, Cooper Consumer Health, over-the-counter, OTC, divestiture, transaction agreement, regulatory approvals, purchase price adjustment, contingent consideration, asset sale